HEALTHQUARTZ
Merck won FDA approval for the first cholesterol pill to rival powerful injectables
Merck received FDA approval for Lipfendra, a once-daily cholesterol pill that reduced LDL cholesterol by up to 59% in late-stage trials, making it a competitor to existing injectable treatments.
Related Signal
Adjacent reporting
- FDA approves new pill to slash cholesterol levels
- U.S. approves pill for cholesterol that drives levels down far below statins
- STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
- STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
- The use of cholesterol medication may stop cancer – and more health headlines